Hong Kong
· Delayed Price · Currency is HKD Keymed Biosciences Statistics
Total Valuation
Keymed Biosciences has a market cap or net worth of HKD 11.59 billion. The enterprise value is 9.63 billion.
| Market Cap | 11.59B |
| Enterprise Value | 9.63B |
Important Dates
The next estimated earnings date is Wednesday, November 27, 2024.
| Earnings Date | Nov 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Keymed Biosciences has 275.60 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Shares Outstanding | 275.60M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 31.26% |
| Float | 184.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 125.33 |
| PB Ratio | 4.09 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.06 |
| EV / Sales | 109.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.02 |
Financial Position
The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.28.
| Current Ratio | 4.98 |
| Quick Ratio | 4.68 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.84 |
| Interest Coverage | -49.47 |
Financial Efficiency
Return on equity (ROE) is -24.70% and return on invested capital (ROIC) is -14.63%.
| Return on Equity (ROE) | -24.70% |
| Return on Assets (ROA) | -13.19% |
| Return on Capital (ROIC) | -14.63% |
| Revenue Per Employee | 78,616 |
| Profits Per Employee | -715,435 |
| Employee Count | 927 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.90% in the last 52 weeks. The beta is -0.08, so Keymed Biosciences's price volatility has been lower than the market average.
| Beta (5Y) | -0.08 |
| 52-Week Price Change | -19.90% |
| 50-Day Moving Average | 35.86 |
| 200-Day Moving Average | 35.29 |
| Relative Strength Index (RSI) | 56.90 |
| Average Volume (20 Days) | 2,105,674 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Keymed Biosciences had revenue of HKD 87.74 million and -798.43 million in losses. Loss per share was -3.06.
| Revenue | 87.74M |
| Gross Profit | 60.23M |
| Operating Income | -892.34M |
| Pretax Income | -789.60M |
| Net Income | -798.43M |
| EBITDA | -816.29M |
| EBIT | -892.34M |
| Loss Per Share | -3.06 |
Balance Sheet
The company has 2.77 billion in cash and 807.31 million in debt, giving a net cash position of 1.96 billion or 7.12 per share.
| Cash & Cash Equivalents | 2.77B |
| Total Debt | 807.31M |
| Net Cash | 1.96B |
| Net Cash Per Share | 7.12 |
| Equity (Book Value) | 2.83B |
| Book Value Per Share | 10.28 |
| Working Capital | 2.39B |
Cash Flow
In the last 12 months, operating cash flow was -762.01 million and capital expenditures -198.50 million, giving a free cash flow of -960.52 million.
| Operating Cash Flow | -762.01M |
| Capital Expenditures | -198.50M |
| Free Cash Flow | -960.52M |
| FCF Per Share | -3.49 |
Margins
| Gross Margin | 68.65% |
| Operating Margin | -1,017.07% |
| Pretax Margin | -899.98% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,094.78% |
Dividends & Yields
Keymed Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.22% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Keymed Biosciences has an Altman Z-Score of 3.47.
| Altman Z-Score | 3.47 |
| Piotroski F-Score | n/a |